AKT signalling is required for ribosomal RNA synthesis and progression of Eμ-Myc B-cell lymphoma in vivo

Devlin, Jennifer R., Hannan,Katherine M., Ng, Pui Y., Bywater, Megan J., Shortt, Jake, Cullinane, Carleen, McArthur, Grant A., Johnstone, Ricky W., Hannan, Ross D. and Pearson, Richard B. (2013). AKT signalling is required for ribosomal RNA synthesis and progression of Eμ-Myc B-cell lymphoma in vivo. In: Special Issue – Signalling. Ca2+ signalling and transport in health and disease, Aarhus, Denmark, (5307-5316). 19 -20 June 2012. doi:10.1111/febs.12135


Author Devlin, Jennifer R.
Hannan,Katherine M.
Ng, Pui Y.
Bywater, Megan J.
Shortt, Jake
Cullinane, Carleen
McArthur, Grant A.
Johnstone, Ricky W.
Hannan, Ross D.
Pearson, Richard B.
Title of paper AKT signalling is required for ribosomal RNA synthesis and progression of Eμ-Myc B-cell lymphoma in vivo
Conference name Ca2+ signalling and transport in health and disease
Conference location Aarhus, Denmark
Conference dates 19 -20 June 2012
Proceedings title Special Issue – Signalling   Check publisher's open access policy
Journal name FEBS Journal   Check publisher's open access policy
Place of Publication Chichester, West Sussex, United Kingdom
Publisher Wiley-Blackwell Publishing Ltd.
Publication Year 2013
Year available 2013
Sub-type Fully published paper
DOI 10.1111/febs.12135
ISSN 1742-464X
Volume 280
Issue 21
Start page 5307
End page 5316
Total pages 10
Language eng
Abstract/Summary The dysregulation of PI3K/AKT/mTORC1 signalling and/or hyperactivation of MYC are observed in a high proportion of human cancers, and together they form a 'super signalling' network mediating malignancy. A fundamental downstream action of this signalling network is up-regulation of ribosome biogenesis and subsequent alterations in the patterns of translation and increased protein synthesis, which are thought to be critical for AKT/MYC-driven oncogenesis. We have demonstrated that AKT and MYC cooperate to drive ribosomal DNA (rDNA) transcription and ribosome biogenesis, with AKT being essential for rDNA transcription and in vitro survival of lymphoma cells isolated from a MYC-driven model of B-cell lymphoma (Eμ-Myc) [Chan JC et al., (2011) Science Signalling 4, ra56]. Here we show that the allosteric AKT inhibitor MK-2206 rapidly and potently antagonizes rDNA transcription in Eμ-Myc B-cell lymphomas in vivo, and this is associated with a rapid reduction in indicators of disease burden, including spleen weight and the abundance of tumour cells in both the circulation and lymph nodes. Extended treatment of tumour-bearing mice with MK-2206 resulted in a significant delay in disease progression, associated with increased B-cell lymphoma apoptosis. Our findings suggest that malignant diseases characterized by unrestrained ribosome biogenesis may be vulnerable to therapeutic strategies that target the PI3K/AKT/mTORC1/MYC growth control network. Hyperactivation of PI3K/AKT and/or MYC signalling activity is observed in many cancers and results in increased ribosome biogenesis thought to be critical for oncogenesis. We show that AKT inhibition antagonizes rDNA transcription in Eμ-Myc lymphoma and this is associated with delayed disease progression in vivo. Thus cancers characterized by unrestrained ribosome biogenesis may be vulnerable to therapies targeting PI3K/AKT signalling. © 2013 The Authors Journal compilation
Subjects 1303 Specialist Studies in Education
1307 Cell Biology
1312 Molecular Biology
Keyword Lymphoma
Oncogenesis
Ribosome biogenesis
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Conference Paper
Collections: Official 2014 Collection
School of Biomedical Sciences Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 11 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 12 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Fri, 29 Nov 2013, 06:45:50 EST by System User on behalf of School of Biomedical Sciences